Guest post from Paul Cole, Lucas & Co., UK; introduction by Warren Woessner. In this interesting note, Paul Cole explores the possible effect on the Fed. Cir. and Supreme Court’s decisions about the patent-eligibility of “genomic DNA” of the arguable failure of the claims to meet the written description and enablement requirements of section 112. [...]
The post The Unacknowledged Role of Section 112 in the Myriad Decisions appeared first on Biotechnology Patent Law Blog | Patents4Life by Warren Woessner.